Navigation Links
Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
Date:11/28/2008

AMSTERDAM, Nov. 28 /PRNewswire/ -- Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR(TM), a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end stage leukemia patients. Under the agreement Professor Velardi will continue the development on the selective depletion of allo-reactive T cells from mismatched donors using Kiadis Pharma's ATIR(TM). Kiadis Pharma is preparing for a multi-center pivotal study on ATIR(TM) to start early 2009 and Professor Velardi will participate in this upcoming study.

"We are very pleased with our continued collaboration with the University of Perugia and Professor Velardi, who is a leader in the field of mismatched bone marrow transplantations," says Dr. Manja Bouman, CEO of Kiadis Pharma. "This collaboration is an important milestone in the development of ATIR(TM) as a revolutionary approach to provide safe and potentially life-saving mismatched bone marrow transplantations as a treatment option for end-stage leukemia patients."

Professor Andrea Velardi says: "So far, we have treated 25 blood cancer patients who have received bone marrow from mismatched donors, including donor immune cells that are selectively depleted of cells causing acute Graft versus Host Disease using the ATIR(TM) process. The results so far are promising and I am therefore very pleased to continue to work with Kiadis Pharma in this field."

For the complete press release please go to: www.kiadis.com/news

About Kiadis Pharma

Kiadis Pharma is an oncology focused pharmaceutical development company with three products in different p
'/>"/>

SOURCE Kiadis Pharma
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
2. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Hearing Scheduled in the Delaware Court of Chancery for August 27, 2007 to Establish the Valid Approval and Consummation of the Merger Between PharmAthene, Inc. and Healthcare Acquisition Corp.
5. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. Proceedings to Affirm Merger Between PharmAthene and Healthcare Acquisition Corp Initiated in Delaware Chancery Court
9. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
10. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
11. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... September 19, 2014 Follow ... potential to revolutionize the world has attracted diverse ... and small start-ups. The early years of nanotechnology ... largely due to the high risks involved, which ... earmarked for this evolving technology have been growing ...
(Date:9/19/2014)... BioTech News Coverage: Progress made ... of studies and trials.  Companies in focus are: GenSpera ... LLY ), Gilead Sciences Inc. (NASDAQ: ... and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) GenSpera, ... for the treatment of cancer, announced that the United ...
(Date:9/19/2014)... , September 19, 2014 The ... Spain , available today on PharmaBoardroom.com ... the Eurozone crisis that rocked the Spanish economy in 2009, ... Spanish pharma community has remained pragmatic in times of trouble. ... is still the fifth biggest European market, and the general ...
(Date:9/18/2014)... 2014 A novel robotic system that ... is currently being tested as part of a biomedical ... Boston with the aim of determining if the robot, ... cancer biopsies faster, more accurate, less costly, and less ... the potential to deliver prostate cancer therapies with greater ...
Breaking Biology Technology:Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 2Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 3Growing R&D Investments & Developments in Nanomaterials to Drive the Global Nanotechnology Market, According to New Report by Global Industry Analysts, Inc. 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7PharmaBoardroom Releases New Spain Pharmaceuticals Report 2PharmaBoardroom Releases New Spain Pharmaceuticals Report 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 2Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 3Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 4Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 5Worcester Polytechnic Institute Participates in Clinical Trial for MRI-Compatible Robot Designed to Improve Accuracy of Prostate Cancer Biopsies 6
... Calif., May 20 Beckman Coulter, Inc. (NYSE: ... of products that simplify, automate and innovate complex biomedical ... of shares of its common stock, the proceeds of ... the previously announced acquisition of the diagnostic systems portion ...
... - Angiotech Pharmaceuticals, Inc. (NASDAQ: ANPI ... partner, Boston Scientific Corporation (NYSE: BSX ... of patients with left main coronary disease who ... Stent System. SYNTAX-LE MANS is a substudy of ...
... In an eleventh-hour attempt to smear Ted Karkus, The ... press release claiming that there was some improper financial arrangement ... subsidiary of Quigley, and Mr. Ted Karkus, who leads a ... of Quigley,s Board of Directors for election at the annual ...
Cached Biology Technology:Beckman Coulter, Inc. Announces Pricing of Common Stock Offering 2Beckman Coulter, Inc. Announces Pricing of Common Stock Offering 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 2SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 3SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 4SYNTAX substudy shows positive outcomes for left main patients treated with TAXUS(R) Express(2)(R) Stent System 5In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 2In Eleventh-Hour Smear Attempt, Quigley Management Sacrifices Key Employee of its Pharma Division 3
(Date:9/18/2014)... located deep in the primitive brainstem has revealed how ... Harvard School of Medicine and the University at Buffalo ... the second "sleep node" identified in the mammalian brain ... to produce deep sleep. , Published online in August ... fully half of all of the brain,s sleep-promoting activity ...
(Date:9/18/2014)... novel robotic system that can operate inside the bore ... part of a biomedical research partnership program at Brigham ... determining if the robot, in conjunction with real-time MRI ... less costly, and less discomforting for the patient. The ... cancer therapies with greater precision. , Developed by a ...
(Date:9/18/2014)... No matter how many times it,s demonstrated, it,s ... creatures. , But by using a signaling ... alter their behavior to suit their population. In ... are present, and act accordingly. , Once the ... may change from innocuous to pathogenic, or from ...
Breaking Biology News(10 mins):No sedative necessary: Scientists discover new 'sleep node' in the brain 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5Researchers study vital 'on/off switches' that control when bacteria turn deadly 2Researchers study vital 'on/off switches' that control when bacteria turn deadly 3
... female frogs in a tiny rainforest outpost of Australia ... 8,000 years or less, according to scientists from the ... the Queensland Parks and Wildlife Service. , "That's lightning-fast," ... UC Berkeley and director of the Museum of Vertebrate ...
... culminated in a study published in this week's Science that ... or prevent East Coast fever. , The disease, which kills ... has had a devastating impact on rural areas ?such as ... role in the local society and economies. The fever is ...
... a single gene can result in two immune ... frequent or unusually severe infections, according to new ... Genetics. The discovery may lead to new diagnostic ... (IgA) deficiency and common variable immunodeficiency (CVID). Currently, ...
Cached Biology News:Picky female frogs drive evolution of new species in less than 8,000 years 2Picky female frogs drive evolution of new species in less than 8,000 years 3Picky female frogs drive evolution of new species in less than 8,000 years 4US/African project deciphers deadly parasite genome 2US/African project deciphers deadly parasite genome 3Defective Gene Linked to Two Inherited Immune Deficiencies 2Defective Gene Linked to Two Inherited Immune Deficiencies 3